Change in 21-gene recurrence score (RS) (Oncotype DX) after exposure to neoadjuvant endocrine therapy.

被引：0
|
作者：
Hilal, Talal
Mi, Lanyu
Anderson, Karen S.
Pockaj, Barbara A.
Gray, Richard J.
Dixon, Leslie E.
Martinez, Erika D.
Singh, Charanjit
Northfelt, Donald W.
机构：
[1] Mayo Clin, Div Hematol & Oncol, Dept Internal Med, Phoenix, AZ USA
[2] Mayo Clin, Phoenix, AZ USA
[3] Arizona State Univ, Temple, TX USA
[4] Mayo Clin Arizona, Scottsdale, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e12650
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12650
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Effect of mammographic density change on endocrine responsiveness independent of tumor biology associated with 21-gene recurrence score.
    Ahn, Sung Gwe
    Lee, Ha K. Woo
    Lim, Jong Won
    Jeong, Joon
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Association of 21-gene recurrence score results with surgical intervention received after neoadjuvant hormonal therapy: Secondary endpoints of the TransNEOS validation study
    Iwata, Hiroji
    Masuda, Norikazu
    Yamamoto, Yutaka
    Fujisawa, Tomomi
    Toyama, Tatsuya
    Kashiwaba, Masahiro
    Ohtani, Shoichiro
    Taira, Naruto
    Sakai, Takehiko
    Hasegawa, Yoshie
    Nakamura, Rikiya
    Akabane, Hiromitsu
    Shibahara, Yukiko
    Sasano, Hironobu
    Yamaguchi, Takuhiro
    Sakamaki, Kentaro
    McCullough, Debbie
    Sugiyama, Naoko
    Chao, Calvin
    Ohasahi, Yasuo
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : 265 - 266
  • [33] Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
    Speers, Corey W.
    Symmans, W. Fraser
    Barlow, William E.
    Trevarton, Alex
    The, Stephanie
    Du, Lili
    Rae, James M.
    Shak, Steven
    Baehner, Rick
    Sharma, Priyanka
    Pusztai, Lajos
    Hortobagyi, Gabriel N.
    Hayes, Daniel F.
    Albain, Kathy S.
    Godwin, Andrew
    Thompson, Alastair
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (10) : 1841 - +
  • [34] Use of Adjuvant Chemoendocrine Therapy vs Adjuvant Endocrine Therapy in Node-Negative Early-Stage Breast Cancer Patients Stratified as Midrange Risk by 21-Gene Oncotype DX Breast Recurrence Score Assay: A MetaAnalysis Study
    Gonong, Patrick Adrian G.
    Torillo, Maila Rose L.
    Lao, Linelle Stacy T.
    Soliven, Albert U.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2019, 229 (04) : S41 - S42
  • [35] Obesity at diagnosis and breast cancer (BC) recurrence risk based on the 21-gene assay recurrence score (RS).
    Ridolfi, Kimberly
    Zhang, Chong
    Onitilo, Adedayo A.
    Ledesma, Wendy M.
    Andreason, Molly
    Engel, Jessica Marie
    Kim, KyungMann
    Wisinski, Kari Braun
    Tevaarwerk, Amye
    Charlson, John A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Impact of exogenous female hormone use (EHU) on breast cancer (BC) recurrence as assessed by the 21-gene assay (Oncotype DX).
    Ledesma, Wendy M.
    Onitilo, Adedayo A.
    Zhang, Chong
    Kim, KyungMann
    Andreason, Molly
    Charlson, John A.
    Ridolfi, Kimberly
    Engel, Jessica Marie
    Wisinski, Kari Braun
    Millholland, Robert
    Dean, James T.
    Tevaarwerk, Amye
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Prediction of response to neoadjuvant hormonal therapy (NAHT) using upfront oncotype Dx recurrence score (RS): Results from the SAFIA phase III trial.
    Al-Saleh, Khalid A.
    Bounedjar, Adda
    Oukkal, Mohammed
    Mahfouf, Hasen
    Bouzid, Kamel
    Bensalem, Assia
    Fillali, Taha
    Larbaoui, Blaha
    Kandil, Alaa
    Alfoheidi, Meteb
    Errihani, Hassan
    Ghosn, Marwan
    Abdulaziz, Nashwa A.
    Dabouz, Farida
    Bahadoor, Mohun Ranvir K.
    El Zawahry, Heba Mohamed
    Kullab, Sherif A.
    Nabholtz, Jean-Marc A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Using Oncotype DX Breast Recurrence Score® (RS) assay to define the role of neoadjuvant endocrine therapy (NET) in early-stage hormone receptor positive (HR plus ) breast cancer (BC)
    Taylor, Caitlin
    Foreman, Aimee
    Russell, Christy
    Bandyopdhyay, Dipankar
    Deng, Xiaoyan
    Floyd, Lisa
    Zelnak, Amelia
    O'Regan, Ruth
    Bear, Harry
    Meisel, Jane
    CANCER RESEARCH, 2022, 82 (04)
  • [39] Evaluation of variables that may impact chemotherapy (CT) administration after determination of Oncotype DX (ODX) recurrence score (RS)
    Bowen, Kristina E.
    Gilmore, James W.
    Szabo, Stephen
    Haislip, Sally
    Hassell, Robert
    Cooper, Joseph
    Richardson, Steve
    Fitzgerald, Meghan
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] Clinical and pathological factors associated with Oncotype DX® 21-Gene recurrence score in patients diagnosed with early stage breast cancer in a low-middle income country
    Ferreira, Carolina Cavalcanti Goncalves
    Araujo, Julio
    Moreira, Shermann Brandao Rodrigues
    Buzaid, Antonio
    Gagliato, Debora
    CANCER RESEARCH, 2024, 84 (09)
12345